Latest Headlines

Latest Headlines

Auxilium eyes a Canadian biotech for a tax-cutting merger

Auxilium Pharmaceuticals is merging with Canadian biotech QLT in an all-stock deal designed to both expand its pipeline and slash its corporate tax rate.

QLT signs eye delivery tech option deal with former CEO

QLT has signed an exclusive option agreement with Mati Therapeutics for its punctal plug delivery system, which delivers drugs to the surface of the eye through the tear film.

QLT seeks options for eye drug delivery tech in major shakeup

QLT's new board revealed a multi-pronged effort that will reduce overhead costs and narrow the focus of the Vancouver-based eye drug specialist. And the biotech outfit's Punctal Plug Delivery System failed to make the cut.

Dissidents trigger big shake up at QLT after board coup

The struggling Canadian biotech QLT is bidding its CEO goodbye along with 146 staffers as it pushes ahead toward critical pivotal studies on an experimental therapy.

Fierce's 5 Drug Delivery Companies to Watch

This year we're naming Fierce 's 5 Drug Delivery Companies to Watch. All are making their mark by bringing drug delivery technology into everyday medical device and pharmaceutical use.

QLT's delivery plugs face issues, analyst says

Tear duct plugs to deliver eye drugs face some challenges, such as keeping the tiny devices in place to release treatments. QLT ($QLTI), the Canadian eye drug specialist, has been on pushing ahead

QLT reports success with eye drug delivery, analyst skeptical

Vancouver-based QLT ($QLTI), a developer of plugs inserted at the opening of the tear ducts to deliver eye treatments, is reporting that its latanoprost punctal plug delivery system is certainly...

QLT sells U.S. unit for $230M

Canada's QLT has sold its subsidiary QLT USA to Tolmar Holdings, a Colorado-based private pharma company, for $230 million. QLT USA's lead asset is Eligard, a line of products for prostate cancer. A

QLT stock rockets as acne drug is cleared for takeoff

Shares of QLT rocketed up 55 percent in a tense market yesterday after the biotech finished a lengthy task in persuading the FDA that a blood test should not be required before doctors prescribe its

ALSO NOTED: Nuvelo drug gets fast tracked; QLT brings on Goldman Sachs; and much more...

> Sanofi-Aventis has set up a small executive committee to set strategy, allocate resources and oversee company management, according to anonymous sources who talked to APM Europe. The idea is to